Cost-Effectiveness of Genome-Guided Statin Treatment for Hypercholesterolemia
Key Insights
A multinational cost-utility analysis of the U-PGx PREPARE study demonstrates that panel-based pharmacogenetics-guided treatment can be cost-effective for patients initiating statin therapy.
The study leverages a 12-gene pharmacogenetic panel to prevent adverse drug reactions, with SLCO1B1 (search) variants linked to statin-induced myopathy serving as a key example.
Hypercholesterolemia (search) remains a major global health burden, with elevated LDL-cholesterol contributing significantly to cardiovascular disease (search) mortality and economic costs worldwide.
Pharmacogenomics-guided prescribing is moving closer to routine clinical practice, and a new multinational cost-utility analysis suggests that panel-based genetic testing before statin initiation may offer economic value alongside clinical benefit. The analysis, published in eClinicalMedicine, draws on data from the landmark U-PGx PREPARE study and evaluates whether a 12-gene pharmacogenetic panel can be cost-effective across diverse European healthcare settings.
The findings arrive at a time when hypercholesterolemia (search) continues to impose a staggering global burden. According to the World Health Organization, cardiovascular diseases remain the leading cause of death worldwide. Elevated low-density lipoprotein cholesterol (LDL-C) is among the most significant modifiable risk factors, with Du and colleagues documenting the global burden attributable to high LDL-C from 1990 to 2019. Ferrara and colleagues further quantified the economic toll in a systematic review of cost-of-illness studies, underscoring the financial imperative for more precise lipid-lowering strategies.
The PREPARE Study and Pharmacogenetic Rationale
The U-PGx PREPARE study, published in The Lancet by Swen and colleagues, was an open-label, multicentre, controlled, cluster-randomised crossover implementation study involving a 12-gene pharmacogenetic panel designed to prevent adverse drug reactions. Among the gene-drug pairs included, the SLCO1B1 (search)-statin association stands out: variants in SLCO1B1 are strongly linked to statin-induced myopathy, as first demonstrated in a genomewide study by the SEARCH Collaborative Group. This adverse effect remains a leading cause of statin discontinuation, making pre-emptive genotyping an attractive clinical tool.
Fragoulakis and colleagues performed the cost-utility analysis using patient-level data from PREPARE, applying standardized health economic methods across multiple countries. Their analysis assessed the incremental cost-effectiveness ratio (ICER) of pharmacogenetics-guided treatment compared with standard care, incorporating both direct medical costs and quality-adjusted life years (QALYs).
Clinical Context and Unmet Need
Statins are the cornerstone of both primary and secondary prevention of atherosclerotic cardiovascular disease (search). Almeida and Budoff reviewed the effect of statins on atherosclerotic plaque, confirming their central role in modifying disease progression. Yet adherence remains suboptimal, partly due to musculoskeletal adverse events. Newman and colleagues, in a scientific statement from the American Heart Association, comprehensively reviewed statin safety and associated adverse events, noting that while serious muscle toxicity is rare, even mild myalgia can undermine long-term compliance.
The pharmacogenomic approach targets this gap. By identifying patients carrying SLCO1B1 (search) loss-of-function variants, clinicians can adjust statin choice or dosing—for instance, selecting rosuvastatin over atorvastatin or initiating a lower dose—potentially reducing myopathy incidence and improving persistence.
Economic Evidence Landscape
The new analysis builds on a growing body of health economic literature. Mitchell and colleagues previously developed a discrete event simulation model to assess the economic value of pharmacogenomic testing for statin-induced myopathy in secondary prevention, finding that testing could be cost-effective under certain assumptions. Zhu and colleagues conducted a systematic review of cost-effectiveness evidence for pharmacogenomics-guided cardiovascular treatment, concluding that while promising, the evidence base remained heterogeneous.
The Fragoulakis analysis advances the field by providing multinational, trial-based cost-utility estimates. Their findings indicate that panel-based testing can achieve acceptable ICERs by commonly cited willingness-to-pay thresholds, though results varied across participating countries due to differences in healthcare costs, statin prescribing patterns, and population allele frequencies.
Population Diversity Considerations
Genetic ancestry significantly influences pharmacogenomic variant distribution. Karamperis and colleagues demonstrated that genetic ancestry unravels distinct geographical patterns related to drug toxicity, including statin-related adverse events. Alqasrawi and colleagues provided pharmacogenomic insights into atorvastatin and rosuvastatin adverse effects in the UAE's multiethnic population, highlighting the importance of diverse representation in both research and implementation. Al-Mahayri and colleagues further reported initial findings from a pharmacogenomics implementation pilot in the United Arab Emirates, demonstrating feasibility in highly diverse populations.
Stevenson and colleagues, writing on behalf of the Pharmacogenomics Global Research Network Publications Committee, recently addressed the practical question of who to test and when, emphasizing that implementation strategies must account for local population genetics and healthcare infrastructure.
Ongoing Prospective Trials
The evidence base continues to expand. Stewart and colleagues described the iPHARMGx master protocol and the nested PREVESTATGx clinical trial, a phase IV adaptive randomized clinical trial evaluating efficacy and cost-efficacy of pre-emptive pharmacogenetic genotyping strategies within the Spanish National Health System. Such prospective studies will be critical in moving from retrospective cost-effectiveness modeling to real-world implementation.
Limitations and Future Directions
As noted by Verbelen and colleagues, cost-effectiveness of pharmacogenetic-guided treatment depends heavily on factors including test cost, prevalence of actionable variants, and the effectiveness of genotype-guided prescribing changes. Morris and colleagues, in a systematic review of cost-effectiveness studies for drugs with Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines, found that while many analyses favored pharmacogenetic testing, methodological quality varied considerably.
The Fragoulakis analysis acknowledges these limitations, noting that long-term outcomes were modeled rather than directly observed and that the panel approach means costs are shared across multiple gene-drug pairs, complicating attribution of benefit to any single association.
Nevertheless, the convergence of robust clinical evidence from PREPARE, growing economic data, and increasing availability of pharmacogenomic testing platforms suggests that genome-guided statin prescribing may soon transition from research settings to routine cardiovascular care—provided that implementation strategies are tailored to local populations and healthcare systems.